NCT02420873 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)

Study Title
An Open-label Phase II Study of Lorvotuzumab Mertansine (NCT02420873)

Trial Description
The goal of this clinical research study is to learn if lorvotuzumab mertansine (also known as BB-10901, huN901-DM1, huN901-SPP-DM1, IMGN-901 or IMGN901 TAP) can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.

This trial is sponsored by M.D. Anderson Cancer Center/ ImmunoGen, Inc. [1]

Study Data

  • Condition: Leukemia
  • Interventions:
    • Drugs used in this trial
      • Lorvotuzumab Mertansine (BB-10901 / IMGN-901)
  • Phase: II
  • Estimated Enrollment: 60
  • Start: May 2015
  • Estimated Primary Completion: May 2017
  • Last verified: June 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.